{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T21:25:11Z","timestamp":1775251511305,"version":"3.50.1"},"reference-count":114,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High-dose therapy with stem cell transplantation (SCT) and novel targeted therapies (thalidomide, its more potent analogues, and bortezomib) represent two approaches for overcoming resistance of multiple myeloma (MM) cells to conventional therapies. While it is now clear that dose-intensification improves the outcome in younger patients, long-term remissions are obtained in a minority of patients. Therefore, the impact of novel agents as part of front-line therapy is the objective of ongoing trials. Gene expression profiling (GEP) will help to improve the management of MM not only by identifying prognostic subgroups but also by defining molecular pathways that are associated with these subgroups and that are possible targets for future therapies.<\/jats:p><jats:p>In Section I, Dr. John Shaughnessy describes recent data obtained with GEP of CD138-purified plasma cells from patients with MM. His group has already shown that overexpression of the Wnt signaling inhibitor DKK1 by MM plasma cells blocks osteoblast differentiation and contributes to the development of osteolytic bone lesions. Recent data allow identification of four subgroups of MM in which GEP is highly correlated not only with different clinical characteristics and outcome but also with different cytogenetic abnormalities. In addition, abnormal expression of only three genes (RAN, ZHX-2, CHC1L) is associated with rapid relapses. In the context of intensive therapy with tandem autotransplantations, this model appears to be more powerful than current prognostic models based on standard biologic variables and cytogenetics. Understanding why the dysregulation of these three genes is associated with a more aggressive behavior of the disease will help to define new therapeutic strategies.<\/jats:p><jats:p>In Section II, Dr. Jean-Luc Harousseau presents recent results achieved with tandem autologous SCT (ASCT) and with reduced intensity conditioning (RIC) allogeneic SCT. ASCT is now considered as the standard of care in patients up to 65 years of age. The IFM (Intergroupe Francophone du Myelome) has recently shown that double ASCT is superior to single ASCT. Current results of three other randomized trials confirm that double ASCT is superior, at least in terms of event-free survival. However, patients with poor prognostic features do poorly even after tandem ASCT. Strategies to further improve the outcome of ASCT include more intensive therapies and the use of novel agents such as thalidomide and immunomodulatory analogs (IMiDs) or bortezomib. Results of allogeneic SCT remain disappointing in MM even with T cell\u2013depleted grafts. Preliminary results of a strategy combining ASCT to reduce tumor burden and RIC allogeneic SCT are encouraging, although the follow-up is still short. However, again, patients with chromosome 13 deletions have poor results with RIC. Longer follow-up of ongoing multicentric studies will help to clarify the indications of RIC.<\/jats:p><jats:p>In Section III, Dr. Paul Richardson summarizes current knowledge of novel targeted therapies in MM. A better understanding of interactions between MM cells and bone marrow stromal cells and of the signaling cascades whereby cytokines mediate proliferation, survival, drug resistance and migration of MM cells provide the rationale for testing novel agents in relapsed\/refractory MM.<\/jats:p><jats:p>Increased angiogenesis coupled with the known anti-angiogenesis activity of thalidomide justified its use in refractory MM. The remarkable responses initially achieved prompted a number of clinical studies in different indications and the development of more potent IMIDs. Among them CC-5013 (Revlimid\u00ae) has been tested in Phase I\/II studies and a randomized Phase III study has just been completed.<\/jats:p><jats:p>Blockade of NF-\u03baB using the proteasome inhibitor bortezomib (Velcade\u00ae) may mediate anti-MM activity by inhibiting interleukin (IL)-6 production in stromal cells and other mechanisms of action have been shown in preclinical studies. Based on the promising results of the Phase II trial, a large randomized trial of bortezomib versus dexamethasone has been completed. Studies of bortezomib combined with other drugs are ongoing.<\/jats:p><jats:p>Arsenic trioxide has a number of properties showing that it targets MM cells interacting with the microenvironment. Clinical studies are ongoing as well. Other agents in MM have already been or will probably be translated soon from the bench to the bedside.<\/jats:p>","DOI":"10.1182\/asheducation-2004.1.237","type":"journal-article","created":{"date-parts":[[2004,11,20]],"date-time":"2004-11-20T02:03:01Z","timestamp":1100916181000},"page":"237-256","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":68,"title":["Multiple Myeloma"],"prefix":"10.1182","volume":"2004","author":[{"given":"Jean-Luc","family":"Harousseau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"John","family":"Shaughnessy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021215280607600_R1","unstructured":"Barlogie B, Shaughnessy J, Munshi N, Epstein J. Plasma cell myeloma. In: Beutler E, Lichtman M, Coller B, Kipps T, Seligsohn U, eds. Williams Hematology (ed 6). New York: McGraw-Hill; 2001:1279\u20131304."},{"key":"2020021215280607600_R2","doi-asserted-by":"crossref","unstructured":"Billadeau D, Ahmann G, Greipp P, Van Ness B. The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell. J Exp Med. 1993;178:1023\u20131031.","DOI":"10.1084\/jem.178.3.1023"},{"key":"2020021215280607600_R3","doi-asserted-by":"crossref","unstructured":"Corradini P, Boccadoro M, Voena C, Pileri A. Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas. J Exp Med. 1993;178:1091\u20131096.","DOI":"10.1084\/jem.178.3.1091"},{"key":"2020021215280607600_R4","doi-asserted-by":"crossref","unstructured":"Szczepek AJ, Seeberger K, Wizniak J, Mant MJ, Belch AR, Pilarski LM. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood. 1998;92:2844\u20132855.","DOI":"10.1182\/blood.V92.8.2844"},{"key":"2020021215280607600_R5","doi-asserted-by":"crossref","unstructured":"Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175\u2013187.","DOI":"10.1038\/nrc746"},{"key":"2020021215280607600_R6","doi-asserted-by":"crossref","unstructured":"Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64:1546\u20131558.","DOI":"10.1158\/0008-5472.CAN-03-2876"},{"key":"2020021215280607600_R7","doi-asserted-by":"crossref","unstructured":"Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99:1745\u20131757.","DOI":"10.1182\/blood.V99.5.1745"},{"key":"2020021215280607600_R8","unstructured":"Hardin J, Waddell M, Cheng Z, et al. Toward the development of diagnostic models capable of distinguishing multiple myeloma, MGUS, and normal plasma cells using global gene expression profiles. Stat Appl Genet Mol Biol.2004. In press."},{"key":"2020021215280607600_R9","doi-asserted-by":"crossref","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564\u2013569.","DOI":"10.1056\/NEJMoa01133202"},{"key":"2020021215280607600_R10","doi-asserted-by":"crossref","unstructured":"Zhan F, Tian E, Bumm K, Smith R, Barlogie B, Shaughnessy J, Jr. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood. 2003;101:1128\u20131140.","DOI":"10.1182\/blood-2002-06-1737"},{"key":"2020021215280607600_R11","unstructured":"Shaughnessy J, Zhan F, Tian E, et al. Gene expression profiling of CD19 and CD138-enriched cells from Waldenstrom\u2019s macroglobulinemia (WM) reveals distinct classes and novel WM-specific genes [abstract]. Blood. 2002;100:1227abstract."},{"key":"2020021215280607600_R12","doi-asserted-by":"crossref","unstructured":"Shaughnessy J, Jr., Gabrea A, Qi Y, et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood. 2001;98:217\u2013223.","DOI":"10.1182\/blood.V98.1.217"},{"key":"2020021215280607600_R13","doi-asserted-by":"crossref","unstructured":"Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy J, Jr. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH\/MMSET fusion transcript. Blood. 2003;101:2374\u20132376.","DOI":"10.1182\/blood-2002-09-2801"},{"key":"2020021215280607600_R14","unstructured":"Zhan F, Hardin J, Bumm KH, et al. Global GEP can be used to accurately predict chromosome 13 deletion in MM [abstract]. Blood. 2001;98:1553."},{"key":"2020021215280607600_R15","doi-asserted-by":"crossref","unstructured":"Shaughnessy J, Jacobson J, Sawyer J, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood. 2003;101:3849\u20133856.","DOI":"10.1182\/blood-2002-09-2873"},{"key":"2020021215280607600_R16","doi-asserted-by":"crossref","unstructured":"Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;3492:2483\u20132494.","DOI":"10.1056\/NEJMoa030847"},{"key":"2020021215280607600_R17","doi-asserted-by":"crossref","unstructured":"Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002;1:133\u2013143.","DOI":"10.1016\/S1535-6108(02)00032-6"},{"key":"2020021215280607600_R18","doi-asserted-by":"crossref","unstructured":"Ross ME, Zhou X, Song G, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 2003;102:2951\u20132959.","DOI":"10.1182\/blood-2003-01-0338"},{"key":"2020021215280607600_R19","doi-asserted-by":"crossref","unstructured":"Bullinger L, Dohner K, Bair E, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med. 2004;350:1605\u20131616.","DOI":"10.1056\/NEJMoa031046"},{"key":"2020021215280607600_R20","doi-asserted-by":"crossref","unstructured":"Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350:1617\u20131628.","DOI":"10.1056\/NEJMoa040465"},{"key":"2020021215280607600_R21","doi-asserted-by":"crossref","unstructured":"Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350:1828\u20131837.","DOI":"10.1056\/NEJMoa032520"},{"key":"2020021215280607600_R22","doi-asserted-by":"crossref","unstructured":"Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68\u201374.","DOI":"10.1038\/nm0102-68"},{"key":"2020021215280607600_R23","doi-asserted-by":"crossref","unstructured":"Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937\u20131947.","DOI":"10.1056\/NEJMoa012914"},{"key":"2020021215280607600_R24","unstructured":"Cox DR, Snell EJ. The analysis of binary data (ed Second). London: Chapman & Hall; 1989."},{"key":"2020021215280607600_R25","doi-asserted-by":"crossref","unstructured":"Moore JD. The Ran-GTPase and cell-cycle control. Bioessays. 2001;23:77\u201385.","DOI":"10.1002\/1521-1878(200101)23:1<77::AID-BIES1010>3.0.CO;2-E"},{"key":"2020021215280607600_R26","doi-asserted-by":"crossref","unstructured":"Dasso M. The Ran GTPase: theme and variations. Curr Biol. 2002;12:R502\u2013508.","DOI":"10.1016\/S0960-9822(02)00970-3"},{"key":"2020021215280607600_R27","doi-asserted-by":"crossref","unstructured":"Dasso M. Running on Ran: nuclear transport and the mitotic spindle. Cell. 2001;104:321\u2013324.","DOI":"10.1016\/S0092-8674(01)00218-5"},{"key":"2020021215280607600_R28","doi-asserted-by":"crossref","unstructured":"Solomou EE, Sfikakis PP, Kotsi P, et al. 13q deletion in chronic lymphocytic leukemia: characterization of E4.5, a novel chromosome condensation regulator-like guanine nucleotide exchange factor. Leuk Lymphoma. 2003;44:1579\u20131585.","DOI":"10.1080\/1042819031000099670"},{"key":"2020021215280607600_R29","doi-asserted-by":"crossref","unstructured":"Shaughnessy J, Tian E, Sawyer J, et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood. 2000;96:1505\u20131511.","DOI":"10.1182\/blood.V96.4.1505"},{"key":"2020021215280607600_R30","doi-asserted-by":"crossref","unstructured":"Shaughnessy J, Jr., Tian E, Sawyer J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of Total Therapy II. Br J Haematol. 2003;120:44\u201352.","DOI":"10.1046\/j.1365-2141.2003.03948.x"},{"key":"2020021215280607600_R31","doi-asserted-by":"crossref","unstructured":"Devilder MC, Cadoret E, Cherel M, et al. cDNA cloning, gene characterization and 13q14.3 chromosomal assignment of CHC1-L, a chromosome condensation regulator-like guanine nucleotide exchange factor. Genomics. 1998;54:99\u2013106.","DOI":"10.1006\/geno.1998.5498"},{"key":"2020021215280607600_R32","doi-asserted-by":"crossref","unstructured":"Latil A, Chene L, Mangin P, Fournier G, Berthon P, Cussenot O. Extensive analysis of the 13q14 region in human prostate tumors: DNA analysis and quantitative expression of genes lying in the interval of deletion. Prostate. 2003;57:39\u201350.","DOI":"10.1002\/pros.10272"},{"key":"2020021215280607600_R33","doi-asserted-by":"crossref","unstructured":"Kawata H, Yamada K, Shou Z, et al. Zinc-fingers and homeoboxes (ZHX) 2, a novel member of the ZHX family, functions as a transcriptional repressor. Biochem J. 2003;373:747\u2013757.","DOI":"10.1042\/bj20030171"},{"key":"2020021215280607600_R34","doi-asserted-by":"crossref","unstructured":"Liu X, Zhou B, Xue L, et al. Nuclear factor Y regulation and promoter transactivation of human ribonucleotide reductase subunit M2 gene in a Gemcitabine resistant KB clone. Biochem Pharmacol. 2004;67:1499\u20131511.","DOI":"10.1016\/j.bcp.2003.12.026"},{"key":"2020021215280607600_R35","doi-asserted-by":"crossref","unstructured":"Zhu J, Giannola DM, Zhang Y, Rivera AJ, Emerson SG. NF-Y cooperates with USF1\/2 to induce the hematopoietic expression of HOXB4. Blood. 2003;102:2420\u20132427.","DOI":"10.1182\/blood-2003-01-0251"},{"key":"2020021215280607600_R36","unstructured":"Attal M, Harousseau JL, Stoppa AM, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:1844\u20131845."},{"key":"2020021215280607600_R37","doi-asserted-by":"crossref","unstructured":"Child JA, Morgan GJ, Davies FC, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875\u20131883.","DOI":"10.1056\/NEJMoa022340"},{"key":"2020021215280607600_R38","unstructured":"Fermand JP, Ravaud P, Katsahian S, et al. High dose therapy and autologous blood stem cell transplantation versus conventional treatment in multiple myeloma: results of a randomized trial in 190 patients 55 to 65 years of age [abstract]. Blood. 1999;94 (suppl 1):396a."},{"key":"2020021215280607600_R39","unstructured":"Blade J, Sureda A, Ribera JM, et al. High-dose therapy\/autotransplantation\/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy. Definitive results from Pethema after a median follow-up of 66 months [abstract]. Blood. 2003;102:42a."},{"key":"2020021215280607600_R40","unstructured":"Palumbo A, Bringhen S, Petrucci MT, et al. A prospective randomized trial of intermediate dose melphalan (100 mg\/m2) vs oral melphalan\/prednisone [abstract]. Blood. 2003;102:984a."},{"key":"2020021215280607600_R41","unstructured":"Barlogie B, Kyle R, Anderson K, et al. Comparable survival in multiple myeloma with high dose therapy employing Mel 140mg\/m2 + TBI 12 Gy autotransplants versus standard dose therapy with VBMCP and no benefit from interferon maintenance: results of Intergroup trial S9321 [abstract]. Blood. 2003;102:42a."},{"key":"2020021215280607600_R42","doi-asserted-by":"crossref","unstructured":"Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood. 2004;103:20\u201332.","DOI":"10.1182\/blood-2003-04-1045"},{"key":"2020021215280607600_R43","doi-asserted-by":"crossref","unstructured":"Desikan R, Barlogie B, Sawyer J, et al. Results of high dose therapy for 1000 patients with multiple myeloma: durable complete remission and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95:4008\u20134010.","DOI":"10.1182\/blood.V95.12.4008"},{"key":"2020021215280607600_R44","doi-asserted-by":"crossref","unstructured":"Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplant for newly diagnosed multiple myeloma. Blood. 1999;93:55\u201365.","DOI":"10.1182\/blood.V93.1.55"},{"key":"2020021215280607600_R45","doi-asserted-by":"crossref","unstructured":"Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem cell transplantation for multiple myeloma.N Engl J Med. 2003;349:2495\u20132502.","DOI":"10.1056\/NEJMoa032290"},{"key":"2020021215280607600_R46","unstructured":"Cavo M, Zamagni E, Cellini C, et al. Single versus tandem autologous transplants in multiple myeloma: Italian experience (abstract). The Hematol J. 2003;4:supp 1:560."},{"key":"2020021215280607600_R47","doi-asserted-by":"crossref","unstructured":"Segeren CM, Sonneveld P, Van Der Holt B, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood. 2003;101:2144\u20132151.","DOI":"10.1182\/blood-2002-03-0889"},{"key":"2020021215280607600_R48","unstructured":"Sonneveld P, Van Der Holt B, Segeren CM, et al. Intensive versus double intensive therapy in untreated multiple myeloma. Updated analysis of the prospective phase III study Hovon 24-MM [abstract]. The Hematol J. 2003;4, suppl 1:559\u2013560."},{"key":"2020021215280607600_R49","unstructured":"Fermand JP, Alberti C, Marolleau JP. Single versus double high dose therapy supported with autologous blood stem cell transplantation using unselected or CD34 enriched ABSC: results of a two by two designed randomized trial in 230 young patients with multiple myeloma [abstract]. The Hematol J. 2003;4, suppl 1:S59."},{"key":"2020021215280607600_R50","unstructured":"Goldschmidt H. Single versus double high dose therapy in multiple myeloma: second analysis of the trial GMMG-HD2 [abstract]. Proc Multiple Myeloma 2004 Meeting. Torino, Italy; 22\u201324 April 2004: 119."},{"key":"2020021215280607600_R51","doi-asserted-by":"crossref","unstructured":"Harousseau JL, Attal M. High-dose therapy in multiple myeloma. The Hematol J. 2003;4:163\u2013170.","DOI":"10.1038\/sj.thj.6200259"},{"key":"2020021215280607600_R52","doi-asserted-by":"crossref","unstructured":"Fassas AB, Spencer T, Sawyer J, et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol. 2002;118:1041\u20131047.","DOI":"10.1046\/j.1365-2141.2002.03757.x"},{"key":"2020021215280607600_R53","doi-asserted-by":"crossref","unstructured":"Shaughnessy J, Jacobson J, Sawyer J, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy ensure long-term survival in myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood. 2003;101:3849\u20133856.","DOI":"10.1182\/blood-2002-09-2873"},{"key":"2020021215280607600_R54","doi-asserted-by":"crossref","unstructured":"Jacobson J, Barlogie B, Shaughnessy J, et al. MDS-type abnormalities with myeloma signature karyotype: only 13% 1-year survival despite tandem transplants. Br J Haematol. 2003;122:430\u2013440.","DOI":"10.1046\/j.1365-2141.2003.04455.x"},{"key":"2020021215280607600_R55","doi-asserted-by":"crossref","unstructured":"Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum \u03b22-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood. 2001;97:1566\u20131571.","DOI":"10.1182\/blood.V97.6.1566"},{"key":"2020021215280607600_R56","doi-asserted-by":"crossref","unstructured":"Shaughnessy J, Tian E, Sawyer J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of Total Therapy II. Br J Haematol. 2003;120:44\u201352.","DOI":"10.1046\/j.1365-2141.2003.03948.x"},{"key":"2020021215280607600_R57","doi-asserted-by":"crossref","unstructured":"Moreau P, Facon T, Leleu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma especially in patients receiving intensive chemotherapy. Blood. 2002;100:1579\u20131583.","DOI":"10.1182\/blood-2002-03-0749"},{"key":"2020021215280607600_R58","doi-asserted-by":"crossref","unstructured":"Chang H, Sloan S, Li D, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol. 2004;125:64\u201368.","DOI":"10.1111\/j.1365-2141.2004.04867.x"},{"key":"2020021215280607600_R59","doi-asserted-by":"crossref","unstructured":"Soverini S, Cavo M, Cellini C, et al. Cyclin D overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood. 2003;102:1588\u20131594.","DOI":"10.1182\/blood-2002-12-3789"},{"key":"2020021215280607600_R60","doi-asserted-by":"crossref","unstructured":"Tricot G, Spencer T, Sawyer J, et al. Predicting long-term (&gt; 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol. 2002;116:211\u2013217.","DOI":"10.1046\/j.1365-2141.2002.03231.x"},{"key":"2020021215280607600_R61","unstructured":"Barlogie B, Jacobson J, Sawyer J, et al. Increasing CR frequency as a strategy toward extending event-free survival and overall survival in multiple myeloma: 4-year results of Total Therapy II versus Total Therapy I (abstract). Blood. 2003;102:42a."},{"key":"2020021215280607600_R62","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Blood E, Vesole DH. A randomised phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. J Clin Oncol. 2004;23:558.","DOI":"10.1200\/jco.2004.22.90140.6508"},{"key":"2020021215280607600_R63","doi-asserted-by":"crossref","unstructured":"Gahrton G, Svensson H, Cavo M, et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983\u201393 and 1994\u201398 at European Group for Blood and Marrow Transplantation Centres. Br J Haematol. 2001;113:209\u2013216.","DOI":"10.1046\/j.1365-2141.2001.02726.x"},{"key":"2020021215280607600_R64","doi-asserted-by":"crossref","unstructured":"Lockhorst HM, Wu K, Verdonck LF, et al. The occurrence of graft-versus host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood. 2004;103:4362\u20134364.","DOI":"10.1182\/blood-2003-11-3862"},{"key":"2020021215280607600_R65","doi-asserted-by":"crossref","unstructured":"Alyea E, Weller E, Schlossman R, et al. T-cell depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood. 2001;98:934\u2013939.","DOI":"10.1182\/blood.V98.4.934"},{"key":"2020021215280607600_R66","doi-asserted-by":"crossref","unstructured":"Lockhorst HM, Segeren CM, Verdonck LF, et al. Partially T-cell depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study Hovon 24 MM. J Clin Oncol. 2003;21:1728\u20131733.","DOI":"10.1200\/JCO.2003.04.033"},{"key":"2020021215280607600_R67","doi-asserted-by":"crossref","unstructured":"Giralt S, Aleman A, Anagnostopoulos A, et al. Fludarabine\/Melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2002;30:367\u2013373.","DOI":"10.1038\/sj.bmt.1703652"},{"key":"2020021215280607600_R68","doi-asserted-by":"crossref","unstructured":"Einsele H, Sha\u0308fer HJ, Hebart H, et al. Follow-up of patients with progressive myeloma undergoing allo grafts after reduced-intensity conditioning. Br J Haematol. 2003;121:411\u2013418.","DOI":"10.1046\/j.1365-2141.2003.04299.x"},{"key":"2020021215280607600_R69","doi-asserted-by":"crossref","unstructured":"Badros A, Barlogie B, Spegel E, et al. Improved outcomes of allogeneic transplantation in high-risk multiple myeloma patients after non myeloablative conditioning. J Clin Oncol. 2002;20:1295\u20131303.","DOI":"10.1200\/JCO.20.5.1295"},{"key":"2020021215280607600_R70","doi-asserted-by":"crossref","unstructured":"Kroger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood. 2002;100:755\u2013760.","DOI":"10.1182\/blood-2002-01-0131"},{"key":"2020021215280607600_R71","doi-asserted-by":"crossref","unstructured":"Maloney DG, Molina AJ, Sahebi F, et al. Allografting with non myeloabaltive conditioning following cytoreductive autograft for the treatment of patients with multiple myeloma. Blood. 2003;102:3447\u20133454.","DOI":"10.1182\/blood-2002-09-2955"},{"key":"2020021215280607600_R72","doi-asserted-by":"crossref","unstructured":"Kroger N, Sayer HG, Schwerdtfeger R, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood. 2002;100:3919\u20133924.","DOI":"10.1182\/blood-2002-04-1150"},{"key":"2020021215280607600_R73","unstructured":"Moreau P, Garban F, Facon T, et al. Preliminary results of IFM9903 and IFM9904 protocols comparing autologous followed by miniallotransplantation and double autologous transplantation in high-risk de novo multiple myeloma (abstract). Blood. 2003;102:43a."},{"key":"2020021215280607600_R74","doi-asserted-by":"crossref","unstructured":"Kroger N, Schilling G, Einsele H, et al. Deletion of chromosome b and 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood. 2004;103:4056\u20134061.","DOI":"10.1182\/blood-2003-12-4435"},{"key":"2020021215280607600_R75","doi-asserted-by":"crossref","unstructured":"Anderson KC. Multiple Myeloma. Advances in disease biology: therapeutic implications. Semin Hematol. 2001;38:6\u201310.","DOI":"10.1016\/S0037-1963(01)90088-5"},{"key":"2020021215280607600_R76","doi-asserted-by":"crossref","unstructured":"Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96:2943\u20132950.","DOI":"10.1182\/blood.V96.9.2943"},{"key":"2020021215280607600_R77","unstructured":"Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071\u20133076."},{"key":"2020021215280607600_R78","unstructured":"Hayashi T, Hideshima T, Akiyama M, et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther. 2002;1:851\u2013860."},{"key":"2020021215280607600_R79","doi-asserted-by":"crossref","unstructured":"Alsina M, Fonseca R, Wilson EF, et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic\/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004;103:3271\u20133277.","DOI":"10.1182\/blood-2003-08-2764"},{"key":"2020021215280607600_R80","doi-asserted-by":"crossref","unstructured":"Mitsiades N, Mitsiades CS, Richardson PG, et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003;101:4055\u20134062.","DOI":"10.1182\/blood-2002-11-3514"},{"key":"2020021215280607600_R81","doi-asserted-by":"crossref","unstructured":"Mitsiades CS, Mitsiades N, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A. 2004;101:540\u2013545.","DOI":"10.1073\/pnas.2536759100"},{"key":"2020021215280607600_R82","unstructured":"Mitsiades CS, Mitsiades N, Poulaki V, et al. Hsp90 inhibitors prolong survival in a SCID\/NOD mice model of diffuse multiple myeloma: therapeutic implications. Blood. 2002;100:106a."},{"key":"2020021215280607600_R83","doi-asserted-by":"crossref","unstructured":"Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1\/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002;21:5673\u20135683.","DOI":"10.1038\/sj.onc.1205664"},{"key":"2020021215280607600_R84","doi-asserted-by":"crossref","unstructured":"Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004;5:221\u2013230.","DOI":"10.1016\/S1535-6108(04)00050-9"},{"key":"2020021215280607600_R85","doi-asserted-by":"crossref","unstructured":"Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia. 2003;17:41\u201344.","DOI":"10.1038\/sj.leu.2402745"},{"key":"2020021215280607600_R86","unstructured":"LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002;62:4996\u20135000."},{"key":"2020021215280607600_R87","doi-asserted-by":"crossref","unstructured":"Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063\u20133067.","DOI":"10.1182\/blood-2002-03-0996"},{"key":"2020021215280607600_R88","doi-asserted-by":"crossref","unstructured":"Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609\u20132617.","DOI":"10.1056\/NEJMoa030288"},{"key":"2020021215280607600_R89","doi-asserted-by":"crossref","unstructured":"Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002;99:14374\u201314379.","DOI":"10.1073\/pnas.202445099"},{"key":"2020021215280607600_R90","doi-asserted-by":"crossref","unstructured":"Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003;101:2377\u20132380.","DOI":"10.1182\/blood-2002-06-1768"},{"key":"2020021215280607600_R91","doi-asserted-by":"crossref","unstructured":"Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood. 1996;87:1104\u20131112.","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104"},{"key":"2020021215280607600_R92","doi-asserted-by":"crossref","unstructured":"Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001;98:428\u2013435.","DOI":"10.1182\/blood.V98.2.428"},{"key":"2020021215280607600_R93","doi-asserted-by":"crossref","unstructured":"Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001;20:4519\u20134527.","DOI":"10.1038\/sj.onc.1204623"},{"key":"2020021215280607600_R94","doi-asserted-by":"crossref","unstructured":"Urashima M, Chen BP, Chen S, et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood. 1997;90:754\u2013765.","DOI":"10.1182\/blood.V90.2.754"},{"key":"2020021215280607600_R95","doi-asserted-by":"crossref","unstructured":"Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210\u2013216.","DOI":"10.1182\/blood.V98.1.210"},{"key":"2020021215280607600_R96","doi-asserted-by":"crossref","unstructured":"Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002;99:4079\u20134086.","DOI":"10.1182\/blood.V99.11.4079"},{"key":"2020021215280607600_R97","doi-asserted-by":"crossref","unstructured":"Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565\u20131571.","DOI":"10.1056\/NEJM199911183412102"},{"key":"2020021215280607600_R98","doi-asserted-by":"crossref","unstructured":"Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001;98:492\u2013494.","DOI":"10.1182\/blood.V98.2.492"},{"key":"2020021215280607600_R99","doi-asserted-by":"crossref","unstructured":"Richardson P, Schlossman R, Jagannath S, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc. 2004;79:875\u2013882.","DOI":"10.4065\/79.7.875"},{"key":"2020021215280607600_R100","unstructured":"Offidani M, Marconi M, Corvatta L, Olivieri A, Catarini M, Leoni P. Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study. Haematologica. 2003;88:1432\u20131433."},{"key":"2020021215280607600_R101","doi-asserted-by":"crossref","unstructured":"Srkalovic G, Elson P, Trebisky B, Karam MA, Hussein MA. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. Med Oncol. 2002;19:219\u2013226.","DOI":"10.1385\/MO:19:4:219"},{"key":"2020021215280607600_R102","doi-asserted-by":"crossref","unstructured":"Hussein MA. Modifications to therapy for multiple myeloma: pegylated liposomal Doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide. Oncologist. 2003;8 Suppl 3:39\u201345.","DOI":"10.1634\/theoncologist.8-suppl_3-39"},{"key":"2020021215280607600_R103","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319\u20134323.","DOI":"10.1200\/JCO.2002.02.116"},{"key":"2020021215280607600_R104","doi-asserted-by":"crossref","unstructured":"Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16\u201319.","DOI":"10.1200\/JCO.2003.03.139"},{"key":"2020021215280607600_R105","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Blood E, Vesole DH, Shepard R, Greipp PR. A randomised phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00): a trial coordinated by the Eastern Cooperative Oncology Group. Proc Am Soc Clin Oncol; 2004:558.","DOI":"10.1200\/jco.2004.22.14_suppl.6508"},{"key":"2020021215280607600_R106","unstructured":"Zangari M, Tricot G, Zeldis J, et al. Results of a phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT) [abstract]. Blood. 2001:3226a."},{"key":"2020021215280607600_R107","doi-asserted-by":"crossref","unstructured":"Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol. 2004. In press.","DOI":"10.1200\/JCO.2004.10.052"},{"key":"2020021215280607600_R108","unstructured":"Richardson PG, Barlogie B, Berenson J, et al. Survival, duration of response, and time to progression with bortezomib in patients with relapsed and refractory myeloma: an update. Hematol J. 2004;5:S103."},{"key":"2020021215280607600_R109","unstructured":"Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib vs. dexamethasone in relapsed multiple myeloma: a phase 3 randomized study. Proc Am Soc Clin Oncol. 2004;23:558."},{"key":"2020021215280607600_R110","unstructured":"Yang H, Swift R, Sadler K, et al. A phase I\/II trial of Velcade and melphalan combination therapy (Vc+M) for patients with relapsed or refractory multiple myeloma (MM) [abstract]. Blood. 2003;102:235a."},{"key":"2020021215280607600_R111","unstructured":"Zangari M, Barlogie B, Jacobson J, et al. VTD regimen comprising Velcade (V) + thalidomide (T) and added Dex (D) for non-responders to V + T effects a 57% PR rate among 56 patients with myeloma (M) relapsing after autologous transplant [abstract]. Blood. 2003;102:236a."},{"key":"2020021215280607600_R112","unstructured":"Orlowski RZ, Voorhees P, Garcia R, et al. Phase I study of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory hematologic malignancies [abstract]. Blood. 2003;102:449a."},{"key":"2020021215280607600_R113","unstructured":"Cavenagh JD, Curry N, Stec J, et al. PAD therapy (bortezomib, doxorubicin and dexamethasone) for untreated multiple myeloma (MM) [abstract]. Proc ASCO. 2004;23:568."},{"key":"2020021215280607600_R114","doi-asserted-by":"crossref","unstructured":"Hideshima T, Akiyama M, Hayashi T, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood. 2003;101:703\u2013705.","DOI":"10.1182\/blood-2002-06-1874"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2004\/1\/237\/1634481\/237_256ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2004\/1\/237\/1634481\/237_256ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T05:29:44Z","timestamp":1624944584000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2004\/1\/237\/18686\/Multiple-Myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,1]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2004.1.237","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,1]]}}}